300. IgG4関連疾患 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 57 / 薬物数 : 52 - (DrugBank : 29) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 147

薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
18F-FDG
   Peking Union Medical College Hospital
      2012   Early Phase 1   NCT01665196   China
68GA-fapi
   Peking Union Medical College Hospital
      2019   Early Phase 1   NCT04125511   China
Abatacept
   Massachusetts General Hospital
      2018   Phase 2   NCT03669861   United States
   OSPEDALE SAN RAFFAELE
      2023   Phase 2   EUCTR2022-003916-10-IT   Italy
Acetaminophen
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT04918147   United States
Afucosylated IGG1 kappa monoclonal antibody
   VIELABIO Inc.
      2020   Phase 3   EUCTR2020-000417-33-IT   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
   Viela Bio, Inc.
      2021   Phase 3   EUCTR2020-000417-33-SE   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-PL   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-HU   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-FR   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
   Viela Bio, Inc./Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000417-33-NL   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-DE   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
Baricitinib
   Wen Zhang
      2023   -   NCT05781516   China
Biliary stent
   Peking Union Medical College Hospital
      2016   -   NCT02797665   China
Cetirizina
   VIELABIO Inc.
      2020   Phase 3   EUCTR2020-000417-33-IT   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
CM310
   Beijing Friendship Hospital
      2023   -   NCT05728684   -
Corticosteroids
   Peking Union Medical College Hospital
      2016   -   NCT02797665   China
Diphenhydramine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT04918147   United States
Drug free, IS monotherapy and GC combined with IS
   Peking Union Medical College Hospital
      2019   -   NCT04124861   -
Elotuzumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT04918147   United States
Extra blood draw samples
   Assistance Publique Hopitaux De Marseille
      2012   -   NCT02899039   France
Famotidine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT04918147   United States
Filgotinib
   UMC Utrecht
      2024   Phase 2   NCT06285539   Netherlands
Glucocorticoids
   Principia Biopharma, a Sanofi Company
      2020   Phase 2   NCT04520451   Canada;France;Italy;Spain;United States
   Zhongshan hospital, Fudan University
      2024   Phase 4   ChiCTR2500101050   China
Iguratimod
   Beijing Friendship Hospital Affiliated to Capital Medical University
      2022   Phase 4   ChiCTR2200062904   China
Indigo
   Kamata Ken
      2022   Phase 2   JPRN-jRCTs051210171   -
Inebilizumab
   Amgen
      2020   Phase 3   NCT04540497   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Cardona Ritsuko
      2021   Phase 3   JPRN-jRCT2071210001   Argentina;Australia;Canada;China;France;Germay;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;UK;USA;Ukraine
   VIELABIO Inc.
      2020   Phase 3   EUCTR2020-000417-33-IT   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
   Viela Bio, Inc.
      2021   Phase 3   EUCTR2020-000417-33-SE   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-PL   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-HU   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-FR   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
   Viela Bio, Inc./Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000417-33-NL   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-DE   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
Leflunomide
   Chinese PLA General Hospital
      2016   Phase 4   NCT02703194   China
Lenalidomide
   Mayo Clinic
      2016   Phase 1   NCT02705638   United States
Mayo interactive breath hold monitor
   Mayo Clinic
      2006   -   NCT00588367   United States
Methionine
   Saitama Medical University International Medical Center
      2016   -   JPRN-UMIN000019908   Japan
Methylprednisolone
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT04918147   United States
Metilprednisolone hikma - 1000 MG polvere PER soluzione iniettabile 10 flaconcini IN vetro
   VIELABIO Inc.
      2020   Phase 3   EUCTR2020-000417-33-IT   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
Mycophenolate mofetil
   Peking Union Medical College Hospital
      2023   -   NCT05974683   China
   Wen Zhang
      2023   -   NCT06663618   China
Obexelimab
   Yamaji Hideomi
      2023   Phase 3   JPRN-jRCT2031230189   ARGENTINA;CANADA;CHINA;FRANCE;GERMANY;HONG KONG;HUNGARY;ITALY;Japan;KOREA;MEXICO;NETHERLANDS;POLAND;SPAIN;SWEDEN;TAIWAN;TURKEY;UNITED KINGDOM;UNITED STATES
   Zenas BioPharma (USA), LLC
      2022   Phase 3   NCT05662241   Argentina;Canada;China;France;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Orencia
   OSPEDALE SAN RAFFAELE
      2023   Phase 2   EUCTR2022-003916-10-IT   Italy
Paracetamolo nova argentia - 500 MG compresse 20 compresse
   VIELABIO Inc.
      2020   Phase 3   EUCTR2020-000417-33-IT   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
Perflubutane
   Department of Endoscopy The Jikei University School of Medicine
      2018   -   JPRN-UMIN000030735   Japan
Prednisolone
   Department of Gastroenterology, University of Tokyo
      2010   -   JPRN-UMIN000003804   Japan
   Osaka University
      2016   -   JPRN-UMIN000022633   Japan
   Wen Zhang
      2023   -   NCT05781516   China
Prednison
   Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2020   Phase 4   ChiCTR2000028918   China
   Wen Zhang
      2023   -   NCT06663618   China
Prednisone
   Cardona Ritsuko
      2021   Phase 3   JPRN-jRCT2071210001   Argentina;Australia;Canada;China;France;Germay;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;UK;USA;Ukraine
   Chinese PLA General Hospital
      2016   Phase 4   NCT02703194   China
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT04918147   United States
   Peking Union Medical College Hospital
      2012   Phase 2/Phase 3   NCT01758393   China
Prednisone and belimumab
   Peking Union Medical College Hospital
      2021   Phase 4   NCT04660565   China
Prednisone and mycophenolate mofetil
   Peking Union Medical College Hospital
      2015   Phase 2   NCT02458196   China
Prednisone DOC generici - 5 MG compresse 30 compresse IN blister PVC-pvdc/ALU
   VIELABIO Inc.
      2020   Phase 3   EUCTR2020-000417-33-IT   Australia;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Ukraine;United Kingdom;United States
PRG-1801
   Tongji Hospital
      2024   Early Phase 1   NCT06497387   China
PRG-2311
   Tongji Hospital
      2024   Early Phase 1   NCT06497361   China
PRN1008
   Principia Biopharma Inc.
      2023   Phase 2   EUCTR2022-002959-18-IT   Canada;France;Italy;Spain;United States
Rilzabrutinib
   Principia Biopharma Inc
      2023   Phase 2   EUCTR2022-002959-18-ES   Canada;France;Italy;Spain;United States
   Principia Biopharma Inc.
      2023   Phase 2   EUCTR2022-002959-18-IT   Canada;France;Italy;Spain;United States
   Principia Biopharma, a Sanofi Company
      2020   Phase 2   NCT04520451   Canada;France;Italy;Spain;United States
Rituximab
   Massachusetts General Hospital
      2012   Phase 1/Phase 2   NCT01584388   United States
   Mayo Clinic
      2016   Phase 1   NCT02705638   United States
SAR444671
   Principia Biopharma Inc
      2023   Phase 2   EUCTR2022-002959-18-ES   Canada;France;Italy;Spain;United States
   Principia Biopharma Inc.
      2023   Phase 2   EUCTR2022-002959-18-IT   Canada;France;Italy;Spain;United States
Sirolimus
   Peking Union Medical College Hospital
      2023   Phase 4   ChiCTR2300078767   China
   Peking University International Hospital
      2023   -   NCT05746689   -
T 614
   Wen Zhang
      2017   Phase 4   NCT03368274   China
T cell injection targeting CD19 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2024   -   NCT06361745   China
Telitacicept
   Zhongshan hospital, Fudan University
      2024   Phase 4   ChiCTR2500101050   China
Thalidomide
   Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2020   Phase 4   ChiCTR2000028918   China
Tofacitinib
   Changhai Hospital
      2022   -   NCT05625581   China
Uplizna
   Amgen
      2024   -   NCT06590051   -
   Viela Bio, Inc.
      2021   Phase 3   EUCTR2020-000417-33-SE   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-PL   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Viela Bio, Inc./Horizon Therapeutics Ireland DAC
      2021   Phase 3   EUCTR2020-000417-33-NL   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000417-33-DE   Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
XMAB5871
   Xencor INC
      2019   Phase 3   EUCTR2017-002214-31-IT   Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Xencor, Inc.
      2019   Phase 3   EUCTR2017-002214-31-NL   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2017-002214-31-BE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2016   Phase 2   NCT02725476   United States
      -   Phase 3   EUCTR2017-002214-31-SE   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2017-002214-31-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Zanubrutinib 80 MG
   Matthew C. Baker
      2022   Phase 2   NCT04602598   United States